about
In-Cell Activation of Organo-Osmium(II) Anticancer Complexes.Preparation of organometallic ruthenium-arene-diaminotriazine complexes as binding agents to DNA.Interaction of a ruthenium hexacationic prism with amino acids and biological ligands: ESI mass spectrometry and NMR characterisation of the reaction products.Organometallic anticancer compoundsMetallotherapeutics: novel strategies in drug design.Mirror-image organometallic osmium arene iminopyridine halido complexes exhibit similar potent anticancer activity.Using non-enzymatic chemistry to influence microbial metabolismTransfer hydrogenation catalysis in cells as a new approach to anticancer drug design.Ferrocenyl Quinone Methide-Thiol Adducts as New Antiproliferative Agents: Synthesis, Metabolic Formation from Ferrociphenols, and Oxidative Transformation.Bis-picolinamide Ruthenium(III) Dihalide Complexes: Dichloride-to-Diiodide Exchange Generates Single trans Isomers with High Potency and Cancer Cell Selectivity.Metal-Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation.Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs.A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin.Anticancer activity of metal complexes: involvement of redox processes.Tuning heavy metal compounds for anti-tumor activity: is diversity the key to ruthenium's success?Organometallic compounds: an opportunity for chemical biology?Metal complex catalysis in living biological systems.Ruthenium(ii) p-cymene complexes of a benzimidazole-based ligand capable of VEGFR2 inhibition: hydrolysis, reactivity and cytotoxicity studies.Combining a Ru(ii)-arene complex with a NO-releasing nitrate-ester ligand generates cytotoxic activity.Insights into the in vitro Anticancer Effects of Diruthenium-1.Solvent assisted formation of ruthenium(III) and ruthenium(II) hydrazone complexes in one-pot with potential in vitro cytotoxicity and enhanced LDH, NO and ROS release.Combining [arene-Ru] with azocarboxamide to generate a complex with cytotoxic properties.Cationic arene ruthenium(II) complexes with chelating P-functionalized alkyl phenyl sulfide and sulfoxide ligands as potent anticancer agents.The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.Structure-activity relationships for organometallic osmium arene phenylazopyridine complexes with potent anticancer activity.Synthesis and in vitro anticancer activity of ruthenium-cymene complexes with cyclohexyl-functionalized ethylenediamine-N,N'-diacetate-type ligands.Arene ruthenium complexes as anticancer agents.Ruthenium- and osmium-arene complexes of 8-substituted indolo[3,2-c]quinolines: Synthesis, X-ray diffraction structures, spectroscopic properties, and antiproliferative activity.Contrasting Anticancer Activity of Half-Sandwich Iridium(III) Complexes Bearing Functionally Diverse 2-Phenylpyridine Ligands.Controlling Platinum, Ruthenium and Osmium Reactivity for Anticancer Drug Design.Histone-deacetylase-targeted fluorescent ruthenium(II) polypyridyl complexes as potent anticancer agents.Thiomaltol-Based Organometallic Complexes with 1-Methylimidazole as Leaving Group: Synthesis, Stability, and Biological Behavior.Photoactive platinum(ii) β-diketonates as dual action anticancer agents.Catalytic Radical Reduction in Aqueous Solution by a Ruthenium Hydride Intermediate.From a decomposition product to an efficient and versatile catalyst: the [Ru(η5-indenyl)(PPh3)2Cl] story.Designing organometallic compounds for catalysis and therapy.Catalytic Metallodrugs: Substrate-Selective Metal Catalysts as Therapeutics.Flexible Modulation of CO-Release Using Various Nuclearity of Metal Carbonyl Clusters on Graphene Oxide for Stroke Remediation.Tumor-targeted supramolecular nanoparticles self-assembled from a ruthenium-β-cyclodextrin complex and an adamantane-functionalized peptide.Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development.
P2860
Q33626165-58579B68-B0BB-4A5F-BA30-5C3D790825DAQ34151556-3C75658B-8963-4C45-B7E1-DEC8F9951983Q34327703-587ACD34-8C16-4F6E-A3E1-8857EFE91573Q34476685-D9FD101C-0CD2-469E-ABCB-08E37C6BA515Q34775956-0FFE5AB7-E894-4106-BB0C-EAF2BA5BCC1CQ34795234-E552BD21-5D33-42E6-82E5-D82EBACB060BQ35235881-2489451A-D85E-4837-B001-90A86257C2C3Q35247064-8D37BB16-FD32-40B5-81EA-7DE48CE99B34Q36045117-4E44E314-ECAE-4523-9305-D69D4F249AE0Q36287265-CC157D45-14AD-425C-8BB6-C8769D32F107Q36613535-9CA41352-48A0-4C91-A896-DEDC5DE879FCQ37603642-4A3A4EF9-8084-4393-9C5F-7971F41FC4AAQ37709331-5DF83189-A2A2-47DA-B9FA-910683CDC479Q37833099-998BD0B5-3A85-4B19-B135-24D7B9610FF5Q37855894-F6210EA5-CC8C-4A77-8953-92E237310139Q38012429-C0F49FAD-5270-46F2-950C-6DE79BD2AF88Q38068312-B2CF080D-1DF7-4DC6-9A49-8DDB0FC28E9EQ38699445-66896E5D-4648-48E7-AB23-20C683A45549Q38734166-A2A6BF2C-4F6E-4443-A187-94E36A3867A2Q38750151-E49B73EC-7924-437B-8CFC-A8496E56F5C8Q38809475-FF3CFD8C-86A2-4AE5-8E13-A2D86ACAC02DQ38942212-FF823A21-4594-4B18-A464-98A79B2AABAFQ39206559-4547C89F-DD79-474B-A55E-A9B241FBAB97Q39400527-802854EC-E884-4ADD-8935-1CC03F873E1FQ39485992-36CAFE06-C521-4A1A-AFD9-23E7B44AD7B8Q39497208-56067764-120D-4640-B3E1-AAC55BCEDDD6Q39706669-33C20EA1-365F-4228-A831-CE8CE3FB9B8BQ41642755-8059DC01-F0B5-4A67-BA9B-52B11B89E3E0Q42400560-3D6E8225-B266-4EB4-81F1-99D8D5E9B1D2Q42576712-57A1D1DF-7981-4486-898B-8D5157347359Q46157208-D04B7E63-412E-43CD-8F21-89AEEAC42518Q46475362-506104F7-E71C-4BE2-8DA6-792DAA7301EAQ46506519-45772F08-1DF4-454C-991A-4113142CA300Q46538652-D62E7E9B-77E0-4C87-8A13-BB31AAE6FAB3Q47131677-CE8CAE90-763C-4E7A-ABEE-255C96DD0207Q48007506-622773AE-CB9A-4EDF-8FEE-3A9AD99DA494Q48157762-488F7290-AED2-451E-A410-194295DBD807Q48255101-B8E54C4C-39D3-472C-80E1-C202AB58871CQ48913126-8FFC4EEB-DF11-48B2-A380-2509ECA3150EQ49687144-E16DF1C3-8FD4-4BD8-A4FF-C27B4D2A1ADD
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Catalytic organometallic anticancer complexes
@en
type
label
Catalytic organometallic anticancer complexes
@en
prefLabel
Catalytic organometallic anticancer complexes
@en
P2093
P2860
P356
P1476
Catalytic organometallic anticancer complexes
@en
P2093
Peter J Sadler
Sarah E McHale
Sarah J Dougan
Simon Parsons
P2860
P304
11628-11633
P356
10.1073/PNAS.0800076105
P407
P577
2008-08-07T00:00:00Z